Highland Therapeutics reports positive results from Phase I study of HLD-200

Canada-based Highland Therapeutics has reported positive results from a Phase I study of a novel formulation of methylphenidate, HLD-200, to treat attention-deficit/hyperactivity disorder (ADHD).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news